Evidence - Francis Medical

Francis Medical is dedicated to acquiring clinical data to understand the use of water vapor ablation to manage prostate cancer. Early results are promising.

Clinical
Study Overview

We continue to build upon our VAPOR 1 and VAPOR 2 clinical studies by partnering with experts in prostate cancer to study Vanquish. Check back for publications and information on new studies.

Multi-Center Pivotal Study (n=235)

VAPOR 2 is a novel, multi-center trial using a transurethral thermal water vapor device (Vanquish) to manage localized intermediate-risk prostate cancer. Enrollment is complete and the 235 patients will be followed for 5 years.

Data published on the first 110 patients with 12-month follow-up demonstrated that:

91% clearance of targeted MRI visible ≥ Grade Group 2 (GG2) disease following a single treatment
Ability to treat anywhere in the prostate
No device-related serious adverse events
93% of patients extremely satisfied or satisfied with the Vanquish procedure
2.7% ≥ Grade 2 urinary incontinence
Low rates of erectile dysfunction

Patients enrolled in the study will have follow-up appointments every 6 months through 5 years.

Vapor 1 Early Feasibility Study (n=15)

Vapor 1 studied the feasibility of treating prostate cancer with water vapor at 4 U.S. sites. Hemiablation was performed…

No serious device-related adverse events reported
No device-related events reported
13/15 (87%) of patients were biopsy-negative for ≥ Gleason pattern 4 disease (Grade Group 2) on the treated side at 6 months

The study demonstrated that water vapor ablation has a low morbidity and it is possible to successfully re-treat residual disease or treat new lesions identified on surveillance, if necessary.

Publications

Transurethral Water Vapor Ablation: Potential for a Novel Prostate Cancer Management Strategy. Research and Reports in Urology, 2025websites2025-10-30T16:52:59-05:00

Transurethral Water Vapor Ablation: Potential for a Novel Prostate Cancer Management Strategy. Research and Reports in Urology, 2025

Purpose: We report results of a prospective, multicenter single-arm study of transurethral vapor ablation (TUVA) of prostate tissue in patients with unilateral, intermediate-risk, localized prostate cancer (PCa).

Warlick CA, Spilseth BD, Dixon CM

Access The Publication

Transurethral Vapor Ablation of Intermediate Risk Localized Prostate Cancer (PCa). Journal of Endourology, 2022websites2025-10-30T16:59:00-05:00

Transurethral Vapor Ablation of Intermediate Risk Localized Prostate Cancer (PCa). Journal of Endourology, 2022

Purpose: Targeted and precise application of thermal energy stored in sterile water vapor is a novel approach to treat cancerous prostate tissue. We report safety and oncological results of transurethral hemigland vapor ablation in a prospective, single-arm study in men with unilateral, intermediate-risk localized prostate cancer.

Christopher M. Dixon, Richard M. Levin, Christopher H. Cantrill, Mikhail Regelman, Benjamin Spilseth, Ronald F. Tutrone Jr., Michael A. White, Aaron J. Milbank, Christopher A. Warlick

Access The Publication

We’re Here
To Help.

We are dedicated to collecting clinical data on our technology. We will continue to update our website with new publications and studies related to Vanquish. Please reach out with questions.

Clinical Evidence